PERSIST results showed that at a dose of 2.5mg idraparinux was at least as effective as existing treatments in VTE prevention.
-
VTE is the third most common cardiovascular disease after heart attack and... -
Risk factors for DVT. -
Idraparinux is a new addition to the synthetic oligosaccharide family of... -
PERSIST, a Phase II dose-ranging study was completed in 2002. -
PERSIST results showed idraparinux was at least as effective as existing...
